Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cisplatin + Xevinapant |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Xevinapant | AT-406|SM-406|Debio1143|Debio-1143|Debio 1143 | SMAC Mimetic 8 | Xevinapant (debio 1143) is a SMAC mimetic, which antagonizes Inhibitor of Apoptosis Protein (IAP) family proteins, resulting in increased tumor cell apoptosis, decreased tumor growth (PMID: 21443232), and may reverse immunosuppression (PMID: 30352911, PMID: 32758455). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04459715 | Phase III | Cisplatin + Xevinapant Cisplatin | A Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 18 |